Teneligliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by Teneligliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4.
Teneligliptin: 20 mg
Any patient with a known hypersensitivity to Teneligliptin or any of the components in the formulation.
Severe ketosis, diabetic coma or history of diabetic coma, type 1 diabetic patients.
Patients with severe infection, surgery, severe trauma (blood sugar control should preferably be done by insulin).